



## SEQUENCE LISTING

<110> Nakamura, Yusuke  
Daigo, Yataro  
Oncotherapy Science, Inc.  
Japan as Represented by  
The President of the University of Tokyo

<120> Methods for Damaging Cells Using Effector Functions of  
Anti-FAM3D Antibodies

<130> 082368-000700US

<140> US 10/809,821

<141> 2004-03-24

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 1322

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (298) .. (972)

<223> FAM3D

<400> 1

```
tcctcaaagg aggggcagag cctgcgagg gcaggagcag ctggcccact ggcgggccgc 60
aacactccgt ctcacctct gggcccactg catctagagg agggccgtct gtgaggccac 120
taccctcca gcaactggga ggtgggactg tcagaagctg gccagggtg gtggtcagct 180
gggtcaggga cctacggcac ctgctggacc acctgcctt ctccatcgaa gcagggaagt 240
gggagcctcg agccctcggg tggaagctga cccaagcca cccttcacct ggacagg 297
atg aga gtg tca ggt gtg ctt cgc ctc ctg gcc ctc atc ttt gcc ata 345
Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile
1 5 10 15
gtc acg aca tgg atg ttt att cga agc tac atg agc ttc agc atg aaa 393
Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys
20 25 30
acc atc cgt ctg cca cgc tgg ctg gca gcc tcg ccc acc aag gag atc 441
Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile
35 40 45
cag gtt aaa aag tac aag tgt ggc ctc atc aag ccc tgc cca gcc aac 489
Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn
50 55 60
tac ttt gcg ttt aaa atc tgc agt ggg gcc gcc aac gtc gtg ggc cct 537
Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro
65 70 75 80
```

```

act atg tgc ttt gaa gac cgc atg atc atg agt cct gtg aaa aac aat 585
Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn
      85                      90                      95

gtg ggc aga ggc cta aac atc gcc ctg gtg aat gga acc acg gga gct 633
Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala
      100                      105                      110

gtg ctg gga cag aag gca ttt gac atg tac tct gga gat gtt atg cac 681
Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His
      115                      120                      125

cta gtg aaa ttc ctt aaa gaa att ccg ggg ggt gca ctg gtg ctg gtg 729
Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val
      130                      135                      140

gcc tcc tac gac gat cca ggg acc aaa atg aac gat gaa agc agg aaa 777
Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys
      145                      150                      155                      160

ctc ttc tct gac ttg ggg agt tcc tac gca aaa caa ctg ggc ttc cgg 825
Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg
      165                      170                      175

gac agc tgg gtc ttc ata gga gcc aaa gac ctc agg ggt aaa agc ccc 873
Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro
      180                      185                      190

ttt gag cag ttc tta aag aac agc cca gac aca aac aaa tac gag gga 921
Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly
      195                      200                      205

tgg cca gag ctg ctg gag atg gag ggc tgc atg ccc ccg aag cca ttt 969
Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
      210                      215                      220

tag ggtggctgtg gctcttcctc agccaggggc ctgaagaagc tcctgcctga 1022
225

cttaggagtc agagcccggc aggggctgag gaggaggagc aggggggtgct gcgtggaagg 1082
tgctgcaggt ccttgcaagc tgtgtcgcg cctctcctct cggaacacaga accctccac 1142
agcacatcct acccggaaga ccagcctcag agggtccttc tggaaccagc tgtctgtgga 1202
gagaatgggg tgctttcgtc agggactgct gacggctggc cctgaggaag gacaaactgc 1262
ccagacttga gcccaattaa attttatttt tgctgggtttt gaatgaaaaa aaaaaaaaaa 1322

<210> 2
<211> 224
<212> PRT
<213> Homo sapiens

<220>
<223> FAM3D

```

&lt;400&gt; 2

Met	Arg	Val	Ser	Gly	Val	Leu	Arg	Leu	Leu	Ala	Leu	Ile	Phe	Ala	Ile
1				5					10					15	
Val	Thr	Thr	Trp	Met	Phe	Ile	Arg	Ser	Tyr	Met	Ser	Phe	Ser	Met	Lys
			20					25					30		
Thr	Ile	Arg	Leu	Pro	Arg	Trp	Leu	Ala	Ala	Ser	Pro	Thr	Lys	Glu	Ile
		35					40					45			
Gln	Val	Lys	Lys	Tyr	Lys	Cys	Gly	Leu	Ile	Lys	Pro	Cys	Pro	Ala	Asn
	50					55					60				
Tyr	Phe	Ala	Phe	Lys	Ile	Cys	Ser	Gly	Ala	Ala	Asn	Val	Val	Gly	Pro
65					70					75					80
Thr	Met	Cys	Phe	Glu	Asp	Arg	Met	Ile	Met	Ser	Pro	Val	Lys	Asn	Asn
				85					90					95	
Val	Gly	Arg	Gly	Leu	Asn	Ile	Ala	Leu	Val	Asn	Gly	Thr	Thr	Gly	Ala
			100					105					110		
Val	Leu	Gly	Gln	Lys	Ala	Phe	Asp	Met	Tyr	Ser	Gly	Asp	Val	Met	His
		115					120					125			
Leu	Val	Lys	Phe	Leu	Lys	Glu	Ile	Pro	Gly	Gly	Ala	Leu	Val	Leu	Val
	130					135					140				
Ala	Ser	Tyr	Asp	Asp	Pro	Gly	Thr	Lys	Met	Asn	Asp	Glu	Ser	Arg	Lys
145					150					155					160
Leu	Phe	Ser	Asp	Leu	Gly	Ser	Ser	Tyr	Ala	Lys	Gln	Leu	Gly	Phe	Arg
				165					170					175	
Asp	Ser	Trp	Val	Phe	Ile	Gly	Ala	Lys	Asp	Leu	Arg	Gly	Lys	Ser	Pro
			180				185						190		
Phe	Glu	Gln	Phe	Leu	Lys	Asn	Ser	Pro	Asp	Thr	Asn	Lys	Tyr	Glu	Gly
		195					200					205			
Trp	Pro	Glu	Leu	Leu	Glu	Met	Glu	Gly	Cys	Met	Pro	Pro	Lys	Pro	Phe
	210					215					220				